<DOC>
	<DOCNO>NCT02296190</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority least 1 dose intranasal ( IN ) MSP-2017 ( Etripamil ) placebo terminate PSVT induced electrophysiology ( EP ) laboratory .</brief_summary>
	<brief_title>Efficacy Safety Intranasal MSP-2017 ( Etripamil ) Conversion PSVT Sinus Rhythm</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , dose-ranging study evaluate effect 4 different dos MSP-2017 ( Etripamil ) subject paroxysmal supraventricular tachycardia . It include 21-day Screening Period , 1-day Treatment Visit , either Follow-up Visit Early Termination Visit occur 12 hour 5 day Treatment Visit . Subjects randomized yield least 100 evaluable subject distribute 5 group least 20 subject .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Supraventricular</mesh_term>
	<criteria>Male female , age 18 year old Screening Has history PSVT Is schedule electrophysiology study catheter ablation Has provide write informed consent Agrees use medically accept form contraception abstinence prevent pregnancy . Males must agree use acceptable form contraception abstinence time study drug administration Followup Visit . Females must agree use acceptable form contraception abstinence Screening 30 day follow study drug administration . Postmenopausal female subject must amenorrheic ≥ 12 month prior Screening ≥ 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) prior Screening , wish use acceptable form contraception abstinence . Acceptable form contraception include : A condom intrauterine device ; A condom hormonal contraception ; A condom diaphragm ; Sterilization subject subject 's partner ( ) ( sterilization procedure must perform 3 month prior ) ; Hysterectomy subject subject 's partner ( ) If female childbearing potential : Has negative serum pregnancy test result Screening ( Screening must occur ≥7 day prior randomization [ ie , Day 7 ] ) Treatment Visit ( prePSVT induction ) ; Has menstrual period within 28 day Treatment Visit . Has history serious allergic reaction verapamil ( especially administer intravenously ) include rash , itch swell ( especially face , tongue , throat ) , severe dizziness , trouble breathing Is currently participate another drug device study , receive investigational drug device within 30 day Screening Has evidence clinically significant cardiovascular , endocrine , gastrointestinal , hematologic , hepatic , immunologic , neurologic , oncologic , pulmonary , psychiatric , renal disease condition , opinion Investigator , would jeopardize safety subject impact validity study result Is female breast feeding , pregnant , plan become pregnant study period Has evidence clinically significant acute chronic condition nasal cavity ( e.g. , rhinitis deviate septum ) could interfere IN administration study drug either nasal cavity Has follow screen Treatment Visit : Systolic blood pressure &lt; 100 mmHg , Diastolic blood pressure &lt; 50 mmHg Has evidence hepatic impairment , define : Alanine aminotransferase aspartate aminotransferase level great equal 3× upper limit normal ( ULN ) Bilirubin level great equal 2× ULN , unless due Gilbert 's syndrome Has evidence renal impairment , define estimate glomerular filtration rate &lt; 30 mL/min ( Modification Diet Renal Disease method ) Has take digoxin , verapamil , diltiazem , Class I , II ( e.g. , beta blocker ) , III antiarrhythmic drug less equivalent 5 halflives drug prior Treatment Visit Has take amiodarone within 30 day Treatment Visit Has take drug abuse , opinion Investigator , would impact validity study result Has myocardial infarction , percutaneous coronary intervention , cerebrovascular accident , transient ischemic attack , unstable angina , acute decompensation heart failure within 6 month Screening Has history evidence second thirddegree atrioventricular block Has implant device ( e.g. , pacemaker , implantable cardioverter defibrillator ) preclude study participation opinion Investigator Study Medical Monitor Has history evidence preexcitation syndrome ( e.g. , WolffParkinson White syndrome , short PR , etc . ) Has evidence QT interval ( Bazett 's correction ) ( QTcB ) &gt; 455 millisecond Screening Treatment Visit Has history evidence familial long QT syndrome , torsades de pointes , ventricular fibrillation , sustain ventricular tachycardia , Brugada syndrome , sudden cardiac death Has evidence recurrent chronic atrial tachycardia , atrial flutter , atrial fibrillation ; could interfere current investigation ; Has history evidence congestive heart failure ( except New York Heart Association Class I ) pulmonary edema In addition , randomized subject meet follow criterion Treatment Visit ( Day 1 ) prior study drug administration , exclude participation study : PSVT induce mechanism PSVT neither AVRT A VNRT It possible sustain episode PSVT 5 minute The subject require continuous sedative ( e.g. , propofol ) , continuous analgesic , inhale anesthetic point time 30 . Minimally necessary dose ( ) benzodiazepine ( ) ( e.g. , midazolam ) and/or narcotic ( ) ( e.g. , fentanyl ) ( give via single multiple administration [ ] ) may use Investigator 's discretion . The identity ( y ) actual administer dose ( ) benzodiazepine ( ) and/or narcotic ( ) record study documentation . Local anesthetic ( ) may use Investigator 's discretion ; use record study documentation The subject undergone prior ablation , subject 's AV node function abnormal opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>